Investing Profile

Carl Gordon

Photo of Carl  Gordon, Managing Partner at OrbiMed

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
OrbiMed Managing Partner
$1M - $75.0M
CompanyStageDateRound SizeTotal Raised
Alterome Therapeutics
Series ANov 2022$35M
Series AJan 2022$64M
Odyssey Therapeutics
Series BOct 2022$170M
Series ADec 2021$220M
Co-investors: Elena Viboch (General Catalyst), Jill carroll (SR One)
Electra Therapeutics
Series BFeb 2022$84M
Co-investors: Beth Seidenberg (Westlake Village BioPartners)
Garuda Therapeutics
Series ASep 2021$72M
Co-investors: Shaan C. Gandhi (Northpond Ventures)
ADARx Pharmaceuticals
Series BSep 2021$75M
Series BAug 2021$50M
Co-investors: Jim Tananbaum (Foresite Capital), Michael Rome (Foresite Capital)
Theseus Pharmaceuticals
Series BApr 2021$100M
Co-investors: Michael Rome (Foresite Capital)
Scribe Therapeutics
Series BMar 2021$100M
Co-investors: Vijay Pande (Andreessen Horowitz)